Effects of AGBL2 on cell proliferation and chemotherapy resistance of gastric cancer.
OBJECTIVE
The present study aimed to investigate the expression status of AGBL2 and its inhibitor latexin, and elucidate their clinical implications in gastric cancer.


METHODS
AGBL2 expression status was examined in gastric cancer cells and 256 gastric cancer specimens by immunohistochemistry staining. The relationship between AGBL2 protein expression and clinicopathological parameters and prognosis was subsequently determined.


RESULTS
AGBL2 expression was determined to be related to pathological tumor and nodal stages by Spearman's regression correlation analysis. The Cox regression test identified AGBL2 protein expression as an independent prognostic factor. AGBL2 and latexin were- found to be related to proliferation and chemotherapy resistance. The 2 proteins also formed immune com- plexes in immunoprecipitation experiments.


CONCLUSIONS
Our results demonstrate that AGBL2 interacts with latexin, regulating the tubulin tyrosination cycle. It is therefore a potential target for intervention.
Haitao
H
Zhu
Zhichao
Z
Zheng
Jianjun
J
Zhang
Xiaoping
X
Liu
Yang
Y
Liu
Wei
W
Yang
Yong
Y
Liu
Tao
T
Zhang
Yan
Y
Zhao
Yanqing
Y
Liu
Xiaohui
X
Su
Xiaohu
X
Gu
D000941:Antigens / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002268:Carboxypeptidases / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D005260:Female; D005743:Gastrectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D034622:RNA Interference; D012307:Risk Factors; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D014162:Transfection; D016896:Treatment Outcome
D000941:Antigens; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C086812:Lxn protein, rat; D002268:Carboxypeptidases; C557716:AGBL2 protein, human